Also trades as: 0J2O.L (LSE) · $vol 0M
HALO NASDAQ
Halozyme Therapeutics, Inc.
1W: +3.3%
1M: +13.8%
3M: +54.3%
YTD: +82.8%
1Y: +94.3%
3Y: +265.5%
5Y: +231.5%
$128.50
+0.49 (+0.38%)
Weekly Expected Move ±4.8%
$114
$120
$126
$132
$138
Credit Risk of going bust: lower than 70% of companies Debt: 12.8% of company value Bonds: $229.7M held by 80 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.58B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.59 (down 99%), Halozyme Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.15B against a stock market value of $14.58B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.18B (short-term plus half of long-term), stock volatility 36.4%; Altman Z'' 3.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
📊 Key Metrics
TTM$2B
Revenue
+41.2% YoY
$414M
Net Income
-25.8% YoY
$806M
Free Cash Flow
+49.1% YoY
83.5%
Gross Margin
59.8%
Op. Margin
47.8%
Net Margin
💰 Income Flow
How revenue becomes profit💵 Cash Flow
Where cash goes🏦 Balance Sheet
Assets = Liabilities + Equity📈 Financial Health
Profitability
ROE173.7%
ROA17.9%
ROIC32.5%
Valuation
P/E36.5
P/B105.0
EV/EBITDA15.0
Leverage
Debt/Equity14.95
Current Ratio2.71
Interest Cov.29.7x
Quality Scores
Piotroski F5/9
Altman Z4.11
Beneish M-2.54